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Abstract
Brain-derived neurotrophic factor (BDNF) regulates a variety of biological processes predominantly via binding to
the transmembrane receptor tyrosine kinase TrkB. It is a potential therapeutic target in numerous neurological,
mental and metabolic disorders. However, the lack of efficient means to deliver BDNF into the body imposes an
insurmountable hurdle to its clinical application. To address this challenge, we initiated a cell-based drug screening
to search for small molecules that act as the TrkB agonist. 7,8-Dihydroxyflavone (7,8-DHF) is our first reported small
molecular TrkB agonist, which has now been extensively validated in various biochemical and cellular systems.
Though binding to the extracellular domain of TrkB, 7,8-DHF triggers TrkB dimerization to induce the downstream
signaling. Notably, 7,8-DHF is orally bioactive that can penetrate the brain blood barrier (BBB) to exert its
neurotrophic activities in the central nervous system. Numerous reports suggest 7,8-DHF processes promising
therapeutic efficacy in various animal disease models that are related to deficient BDNF signaling. In this review, we
summarize our current knowledge on the binding activity and specificity, structure-activity relationship,
pharmacokinetic and metabolism, and the pre-clinical efficacy of 7,8-DHF against some human diseases.
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Background
Neurotrophins (NT) are growth factors that regulate the
development and maintenance of the peripheral and the
central nervous systems [1]. It is a family of secretary
proteins that includes brain-derived neurotrophic factor
(BDNF), nerve growth factor (NGF), NT-3, and NT-4/
NT-5 [2]. BDNF exerts its biological functions on neu-
rons through two transmembrane receptors: the p75
neurotrophin receptor (p75NTR) and the TrkB receptor
tyrosine kinase, while NGF binds to TrkA, NT-4/5 binds
to TrkB, and NT-3 preferentially binds to TrkC [3, 4].
TrkB is one of the most widely distributed neurotrophic
receptors (NTRs) in the brain, which is highly enriched
in the neocortex, hippocampus, striatum, and brainstem
[5]. Binding of BDNF to TrkB receptor triggers its
dimerization through conformational changes and auto-
phosphorylation of tyrosine residues in the intracellular
domain, resulting in activation of signaling pathways involv-
ing mitogen-activated protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PI3K) and phospholipase C-γ
(PLC-γ).
BDNF is of particular therapeutic interest because of
its neurotrophic actions on a number of neuronal popu-
lations including sensory neurons (implicated in periph-
eral sensory neuropathies [6]); motor neurons which are
degenerated in amyotrophic lateral sclerosis (ALS) [7];
dopaminergic neurons of the substantia nigra, which are
lost in Parkinson’s disease (PD); and cholinergic neurons
of the basal forebrain, that play a significant role in in
Alzheimer’s disease (AD) [8]. Moreover, BDNF protects
hippocampal neurons from glutamate toxicity [9], rescues
cerebellar neurons from programmed cell death [10], re-
duces ischemic neuronal injury [11, 12] and improves
functional recovery from postinjury regeneration [13].
Thus, BDNF may represent a beneficial therapeutic agent
against a variety of human disorders such as ALS, AD,
PD, fetal alcohol exposure, autism and schizophrenia [14].
However, the outcomes of several clinical trials using
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recombinant BDNF are disappointing [15, 16], possibly
because of the poor delivery and short in vivo half-life of
BDNF. In addition, BDNF binds to p75NTR, a promiscu-
ous NTR that is known to activate cell death pathways via
recruitment of multiple adaptor proteins [17, 18]. To ad-
dress these problems, tremendous effort has been made to
generate selective agonists of TrkB including monoclonal
antibodies [19] and peptide mimetics [20, 21] . Based on
the fact that a monocyclic monomeric peptide resembling
the a single loop of BDNF (loop 2) acts as an inhibitor of
BDNF-mediated neuronal survival, O’Leary and Hughes
designed bicyclic dimeric peptides that mimic a pair of
solvent-exposed loops for the binding and activation of
TrkB. These dimeric peptides behave as partial agonists of
TrkB with respect to BDNF, which promotes the survival
of embryonic chick sensory neurons in culture [20]. Re-
cently, the tandem repeat peptide agonist approach has
been employed for designing BDNF/NT-4/5 mimetics but
none of these peptidyl compound exhibit satisfactory in
vivo agonistic effect on TrkB [22]. Adenosine and pituit-
ary adenylate cyclase-activating peptide (PACAP) has
also been reported to transactivate TrkB in cultured
hippocampal neurons, however, this G protein-coupled
receptor ligand does not act as TrkB agonists as it only
activates an immature form of TrkB after 1 h treatment
[23–25].
To search for small molecules that mimic the bio-
logical functions of BDNF, we developed a cell-based
TrkB receptor-dependent survival assay system, and
used it to screen a chemical library via counter screen-
ing. The positive hits were then subjected to TrkB activa-
tion analysis in primary neurons and receptor binding
assays. Finally, we identified two lead compounds: 7,8-dihy-
droxyflavone and deoxygedunin [26, 27], which bind to the
receptor extracellular domain of TrkB, promote the recep-
tor dimerization and autophosphorylation, and activate the
downstream signaling cascades. Due to its commercial
availability, and the favorable chemical and physical charac-
teristics, 7,8-DHF is has been extensively explored in a var-
iety of cell types and disease models since its first report in
2010 [26]. In the current review, we will summarize the
main biochemical, physiological, pharmacological and func-
tional activities of 7,8-DHF. Its therapeutic potentials
against neurological and metabolic disorders will also be
discussed.
Discovery of TrkB receptor agonists
In order to identify small molecules that mimic the
neurotrophic activities of BDNF, we developed a cell-
based survival assay using a cell permeable fluorescent
dye MR(DERD)2, which produces red signal upon
caspase-3 cleavage in apoptotic cells. TrkB-lacking SN56
cells (a fusion of N18TG2 neuroblastoma cells with
mouse neurons from postnatal day 21- septa) and its
derived cell line T48 (which is stably transfected with
TrkB) were utilized in our assay. We cultured the cells
in 96-well plates and pre-incubated the cells with com-
pounds from a library for 30 min, followed by stauros-
porine (STS) treatment for 9 h. MR(DEVD)2 was
introduced to the cells 1 h before examination under
fluorescent microscope. The apoptotic cells could be de-
tected by the red signal, while the live cells had no sig-
nal. Using this caspase-activated fluorescent dye as a
visual assay, we screened thousands of compounds from
the Spectrum Collection library. Sixty-six compounds
were found to selectively protect T48, but not SN56
cells, from STS-initiated apoptosis, indicating that these
compounds might act either directly through TrkB re-
ceptor or its downstream signaling effectors. These posi-
tive hits were further analyzed on primary hippocampal
neurons for TrkB activation and neuronal survival. 7,8-
DHF is one of the positive compounds that specifically
activate TrkB, but not TrkA or TrkC, at a concentration
of 250 nM. It is also a bioavailable chemical that can
pass through the BBB to provoke TrkB and its down-
stream PI3K/Akt and MAPK activation in mouse brain
(cortex, hippocampus and hypothalamus) upon intraper-
itoneal or oral administration. In addition to cortical and
hippocampal neurons, 7,8-DHF also protects other cell
types including the RGC (retinal ganglion cells) and
PC12 cells from excitotoxic and oxidative stress-induced
apoptosis and cell death [28–30]. Fitting with these in
vitro neuroprotective actions, 7,8-DHF protects the
RGC cells from excitotoxic and oxidative stress-induced
apoptosis in retinal glaucoma model in a TrkB-
dependent manner [28]. Moreover, 7,8-DHF promotes
the survival and reduces apoptosis in cortical neurons of
TBI (traumatic brain injury) as administration of 7,8-
DHF at 3 h post-injury reduces brain tissue damage via
the PI3K/Akt pathway [31].
To demonstrate that 7,8-DHF indeed is a TrkB specific
agonist, we performed in vitro filter binding assay with
[3H]-labeled 7,8-DHF and purified recombinant TrkB
ECD (extracellular domain) proteins. We showed that
7,8-DHF has a Kd of ~320 nM toward TrkB with a bind-
ing ratio of 1:1 (ligand versus receptor). Similarly, Bio-
core Surface Plasmon Resonance (SPR) and fluorescent
quenching assay support the notion that 7,8-DHF dir-
ectly binds to TrkB ECD with Kd about 15.4 nM. As the
positive control, BDNF displays a Kd of approximately
1.7 nM. These assays also demonstrated that 7,8-DHF
but not 5,7-DHF (5,7-dihydroxyflavone) interacts with
TrkB but not TrkA [32]. The different binding affinities
of 7,8-DHF towards TrkB obtained in these assays might
be a result of distinctive binding principles and experi-
mental conditions. Mapping assays further suggest that
7,8-DHF may directly interact with LRM/CC2 regions of
TrkB ECD [26], a finding that is further supported by an
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subsequent molecular modeling and docking analysis
[33]. Utilizing TrkB-Fc, a His-tagged fusion protein of
human TrkB-ECD (C32-H430), and human IgG1 that
can specifically neutralize BDNF’s agonistic effect on
TrkB, we demonstrated that these agents can antagonize
7,8-DHF’s stimulatory effect, emphasizing that 7,8-DHF
exerts its agonistic activity via binding to TrkB receptor.
We tried to determine the co-crystal structure of 7,8-
DHF and TrkB ECD but no satisfactory results were ob-
tained possibly because of the highly glycosylated nature
of TrkB receptor. Nevertheless, all these independent ex-
periments strongly support that 7,8-DHF indeed prefer-
entially interacts with TrkB but not TrkA or TrkC
receptors. Since no interaction or functional studies have
been performed between 7,8-DHF and the low affinity
BDNF receptor p75NTR, it remains unknown if 7,8-
DHF also activates p75NTR as well.
TrkB receptor internalization by 7,8-DHF
Internalization of the neurotrophin–Trk complex plays
a critical role in signal transduction that initiates cell
body responses to target-derived neurotrophins. The
neurotrophin–Trk complex is internalized through
clathrin-mediated endocytosis, leading to the formation
of signaling endosomes [34, 35]. Using two independent
approaches, we demonstrated that 7,8-DHF treatment
triggers an internalization of activated TrkB to the early
endosomes [32]. First, we analyzed TrkB receptor endo-
cytosis in primary neurons upon BDNF or 7,8-DHF
stimulation using microscopic measurement. While in-
ternalized TrkB receptors colocalized with EEA1, the
early endosome marker, kinetic quantification of the co-
localized TrkB/EEA1 indicates that BDNF is more po-
tent than 7,8-DHF in stimulating TrkB internalization
and early endosomes delivery in the first 10 min. At
60 min stimulation, both BDNF and 7,8-DHF substan-
tially increase TrkB endocytosis and its early endosomal
residency but 7,8-DHF seems more robust than BDNF.
Second, we performed the biotinylation assay by label-
ing the surface protein with sulfo-NHS-SS-biotin,
followed by BDNF or 7,8-DHF stimulation. Internalized
biotinylated proteins were then precipitated with strep-
tavidin, and analyzed by immunoblotting with anti-TrkB
antibody against its ECD domain. Concur with the
microscopic detection, both BDNF and 7,8-DHF
strongly escalate TrkB internalization.
BDNF treatment elicits TrkB receptor ubiquitination
and degradation [36–39]. Our recent report found that
BDNF induced TrkB ubiquitination 10 min after stimu-
lation [32]. Its ubiquitination signals tightly correlates
with its Y817 phosphorylation pattern. Accordingly, the
total level of TrkB is evidently reduced at 180 min, fit-
ting with the previous findings [36–39]. 7,8-DHF treat-
ment swiftly induces TrkB phosphorylation and the
activation sustains for more than 3 h without inducing
TrkB ubiquitination or degradation; by contrast, BDNF-
triggered TrkB Y817 phosphorylation with a peak signal
at 10 min, decreases at 60 min and fades away at
180 min. Clearly, these findings support that 7,8-DHF and
BDNF activate TrkB with different mechanisms. It re-
mains unclear how the activated TrkB signaling induced
by 7,8-DHF is turned off eventually. Conceivably, 7,8-DHF
and BDNF may induce differential to dephosphorylate the
phosphorylated tyrosine residues of TrkB in the signal-
somes within the cytoplasms.
Structure-activity relationship (SAR) study of
7,8-DHF
Flavonoids are a large group of polyphenolic compounds
containing a basic flavan nucleus with two aromatic
rings (the A and the B rings) interconnected by a three-
carbon-atom heterocyclic ring (the C ring). Flavonoids
are divided into several big categories including flavone,
flavonol, flavanone, flavanonol, flavans, anthocyanidins
and isoflavonoids. 5,7-dihydroxylation is commonly
found on the A ring, but 7-hydroxy ring is common in
the isoflavonoids subgroups. The B ring generally has
4′-, 3′,4′- or a 3′,4′5′-hydroxylation pattern. Rare flavo-
noids like 7,8-DHF lack B-ring oxygenation. Flavonoids
are the largest and the most diverse class of plant sec-
ondary metabolites. These compounds are naturally
present in vegetables, fruits, and beverages. Bioflavo-
noids have been known for a long time to exert diverse
biological effects. In particular, they are antioxidants and
preventive agents against cancer [40]. Accumulating evi-
dence suggests that flavonoids have the potential to im-
prove human memory and neuro-cognitive performance
via protecting the vulnerable neurons, enhancing neur-
onal function and stimulating neuronal regeneration
[41]. Flavonoids also exert effects on LTP, one of the
major mechanisms underlying learning,memory and
cognitive performance through their interactions with
the signaling pathways like PI 3-kinase/Akt [42], MAPK
[43, 44] and PKC [45], etc.
The widespread distribution of flavonoids, their variety
and their relatively low toxicity compared to other active
plant compounds (e.g. alkaloids) mean that many ani-
mals, including humans, ingest significant quantities in
their diet. Therefore, we tested a number of commer-
cially available flavonoids for their TrkB agonistic activ-
ities. Our preliminary structural-activity relationship
(SAR) study showed that the 7,8-dihydroxy groups are
essential for the agonistic effect. We also found that the
8-hydroxy group in A ring is essential for the TrkB
stimulatory effect, as 5,7-DHF, 5,6-DHF and 5,6,7-THF
could not activate TrkB. The dihydroxy groups in B ring
displays relatively higher TrkB agonistic activity when
compared to compounds with dihydroxy groups in A
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ring. None of the single hydroxy flavone derivatives ex-
hibited notable TrkB stimulatory effect and no trihy-
droxy flavones or dimethoxy flavones demonstrated any
substantial effect [46].
The presence of 4′-position amino group enhances the
agonistic effect of 7,8-DHF [46], which cannot be re-
placed by a hydroxy group. Interestingly, the 3′ position
hydroxy group escalates 7,8-DHF’s agonistic activity and
improves the hearing of animals thorough protecting
spiral ganglion neurons from degeneration [46–48]. It is
worth noting that the oxygen atom in C ring is also es-
sential for the stimulatory activity as replacing this O
atom with NH group abolishes the agonistic activity of
7,8-DHF. Together, our SAR study suggests that the cat-
echol group (7,8-dihydroxy in A ring) might be indis-
pensable for the agonistic activity and the 4′-hydroxy
group on B ring reduces, whereas 3′-hydroxy group in-
creases its activity.
To optimize the lead compound and conduct more
comprehensive SAR studies, we synthesized dozens of
7,8-DHF derivatives via medicinal chemistry. The first
generation of the optimized derivative is 4′-dimethyla-
mino-7,8-DHF, which possesses higher agonistic effect
on TrkB than the parental compound 7,8-DHF with
longer in vivo activity. Because catechol group contain-
ing compounds usually possess poor pharmacokinetic
profiles, as a part of our effort to optimize the lead
compound 4′-dimethylamino-7,8-DHF, we synthesized
numerous bioisoteres of this compound to enhance its
biological or physical properties. Replacing the 7,8-di-
hydroxy groups with imidazole or urea ring in A-ring
elevates the TrkB agonistic activity than the lead com-
pound. Since the 4′-dimethylamino group is prone to
demethylation during metabolism, we replaced the
dimethylamino group with a pyrrolidino or mono-
methylamino group to address this potential issue. Sev-
eral rounds of organic synthesis of 7,8-DHF derivatives
have been performed and we have obtained a couple of
synthetic benzo-imidazole derivatives displaying EC50
of about 5–10 nM in primary neurons (unpublished
data). Their in vivo pharmacokinetic (PK) profiles and
oral bioavailability are now under investigation.
Cytotoxicity of 7,8-DHF
7,8-DHF treatment did not induce any apparent toxicity
in mice. In one of our studies, we compared the patho-
logical changes induced by 7,8-DHF after feeding
C57BL/6 mice at 5 mg/kg for 3 weeks. No adverse
pathological change was detectable in the drug-treated
kidney, liver, lung, muscle, spleen, cortex, hippocampus,
heart, intestine and testis [46]. In addition, the complete
blood count (CBC) analysis showed that there is no sig-
nificant difference between drug-treated and the control
saline-treated mice [49]. In another long-term feeding
experiment, female mice receiving ~ 2.4 μg 7,8-DHF/day
for 20 weeks also displayed normal CBC values [49].
These data support that 7,8-DHF is not toxic to the mice
during the chronic treatment. Titration experiment also
reveal that 7,8-DHF does not inhibit HEK293 cell prolif-
eration at a dose up to 50 μM [46].
Pharmacokinetics of 7,8-DHF
To study the 7,8-DHF’s PK profiles, we have performed a
panel of in vitro ADMET assays. We found that 7,8-DHF is
stable in liver microsomal assay but labile in hepatocytes,
indicating that 7,8-DHF might be readily subjected to
secondary modification-conjugation. Caco-2 permeability
assay, parallel artificial membrane permeability assay
(PAMPA) and PAMPA-BBB assays demonstrate that 7,8-
DHF possess reasonable absorption rate and is able to
penetrate BBB [50]. MDR1-MDCKII permeability assay
also indicates that 7,8-DHF is a weak P-glycoprotein (Pgp)
substrate (unpublished data). hERG assay reveals that 7,8-
DHF exhibits IC50 >25 μM. CYP inhibition and induction
assays reveal that 7,8-DHF has no time-dependent inhib-
ition nor induction on major CYP enzymes. Concur with
this result, 12 months chronic treatment or high dose acute
treatment with 7,8-DHF suggests that 7,8-DHF is non-toxic
to the rodents.
In vivo PK study shows that plasma 7,8-DHF concentra-
tion peaks at 10 min with 70 ng/ml, and brain 7,8-DHF also
climaxes at 10 min with concentration of 50 ng/g of brain.
7,8-DHF in plasma can still be detected after 8 h (5 ng/ml)
after administration. In contrast, only 7 ng/g of 7,8-DHF
can be found in brain at 4 h and it is below the quantitative
limit at 6 h [50]. In vivo metabolism study shows that 7,8-
DHF is subjected to glucuronidation, sulfation and methy-
lation [33]. Among these modifications, glucuronidation
and sulfation are mainly responsible for the in vivo clear-
ance of the flavonoids. Indeed, O-methylated metabolites
including 7-methoxy-8-hydroxy-flavone (7M8H-flavone)
and 7-hydroxy-8-methoxy-flavone (7H8M-flavone) can be
detected in both the plasma and brain samples after oral
administration of 7,8-DHF. Interestingly, these mono-
methylated metabolites are still active in triggering TrkB ac-
tivation in primary neurons and mouse brain [50].
Catechol containing compounds usually have short
in vivo half-life and are prone to be cleared in the cir-
culation system after oxidation, glucoronidation, sulfa-
tion or methylation. For instance, Apomorphine is a
catechol-containing non-narcotic morphine derivative
that acts as a potent dopaminergic agonist. Its metabolism
occurs through several enzymatic pathways, including N-
demethylation, sulfation, glucuronidation, and catechol-
O-methyltransferase as well as by nonenzymatic oxidation
[51]. L-DOPA is the mainstay of Parkinson’s disease (PD)
therapy; this drug is usually administered orally, but it is
extensively metabolized in the gastrointestinal tract, so
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that relatively little arrives in the bloodstream as intact L-
DOPA. To minimize the conversion to dopamine outside
the central nervous system, L-DOPA is usually given in
combination with inhibitors of amino acid decarboxylase
and COMT (catechol methyltransferase) [52]. Our prelim-
inary in vivo PK study revealed that 7,8-DHF has t1/2 more
than 2 h in mouse circulation after oral administration
[50]. Conceivably, glucuronidation, sulfation and methyla-
tion pathways may explain the relative short half-life of
7,8-DHF and its synthetic derivatives.
To improve the poor PK profiles intrinsic to catechol-
containing molecules, we synthesized numerous prodrugs
by modifying 7,8-dihydroxy groups with esters, carba-
mates or phosphates to improve the oral bioavailability
and brain exposure of 7,8-DHF. Currently, an optimal
prodrug R7 has been found with favorable in vitro
ADMET (absorption, distribution, metabolism, excretion
and toxicity) characteristics. R7 exhibits approximately
18 % oral bioavailability with Cmax of 1554.9 ng/ml, Tmax
of 0.28 h and T1/2 for PO of 2.32 h. Noticeably, 7,8-DHF
plasma concentration released from R7 (PO, 50 mg/kg) is
much higher than orally administrating the same dose of
parent 7,8-DHF. The oral bioavailability is increased from
4.6 % (parental 7,8-DHF) to 84.2 % (R7). Accordingly, the
brain exposure for 7,8-DHF is significantly increased by
R7 than the parent compound upon oral administration of
comparable dosage (unpublished data). TrkB and its
downstream p-Akt/p-MAPK signalings are potently acti-
vated upon oral administration of R7, which is tightly cor-
relating with 7,8-DHF concentrations in the animal brain.
R7-provoked TrkB activation also fits well with the in vivo
PK data, underscoring that the released 7,8-DHF from R7
prodrug triggers a long-lasting TrkB signalings in the
mouse brain. This prodrug is now under preclinical IND-
enabling study for the indication of Alzheimer’s disease.
7,8-DHF displays robust therapeutic efficacy toward
Alzheimer’s disease
There is mounting evidence that 7,8-DHF mimics the
physiological activities of BDNF and exhibits promising
therapeutic efficacy toward various neurological diseases in-
cluding Parkinson’s disease (PD) [26], Huntington’s disease
(HD) [27], ALS (Amyotrophic lateral sclerosis) [53, 54],
Alzheimer’s disease (AD) [55–58], Posttraumatic Stress
Disorder (PTSD) [59], and Rett Syndrome [60]. Moreover,
7,8-DHF displays therapeutic effect toward axon regener-
ation [61], and spiral ganglion degeneration [48]. Notice-
ably, it also demonstrates therapeutic activities in mental
diseases like depression [33, 56, 62, 63]. Here, we focus on
discussing its effects in treating AD, the leading cause of de-
mentia worldwide, which is characterized by the accumula-
tion of the β-amyloid peptide (Aβ) within the brain along
with deposition of hyperphosphorylated and cleaved
microtubule-associated protein Tau. It is suggested that
reductions of BDNF content or TrkB inactivation may play
a role in the pathogenesis of AD. Indeed, BDNF expression
is reduced in the brain of AD patients and delivery of
BDNF gene has been shown as a novel potential thera-
peutic in diverse models related to AD [64]. BDNF also
displays a protective role against AD pathogenesis by
increasing learning and memory of demented animals
[65]. Thus, these preclinical evidence strongly sup-
ports that BDNF might be useful as a therapeutic
agent for treating AD.
Reduced acetylcholine neurotransmission due to loss
of neurons in the basal forebrain and depletion of cho-
line acetyltransferase are observed in AD pathology.
Currently, there are two types of medication to treat
AD: cholinesterase inhibitors and NMDA antagonist.
However, these drugs can only delay the inevitable
symptomatic progression of the disease without elimin-
ating the main neuropathological hallmarks of the dis-
ease (i.e. formation of senile plaques and neurofibrillary
tangles) nor rescuing the neuronal loss. 7,8-DHF po-
tently stimulates hippocampal progenitor neurogenesis.
For instance, oral administration of 7,8-DHF (5 mg/kg)
in wild-type C57BL/6 J mice for a few weeks strongly in-
duces neurogenesis [46]. Intraperitoneal administration
of 7,8-DHF also elicits robust neurogenesis in depressive
vulnerable or non-vulnerable rat [62]. This neurotrophic
effect by 7,8-DHF has also been observed in APP/PS1
AD mouse model [66]. Devi and Ohno showed that 7,8-
DHF rescued memory deficits in transgenic mice that
co-express five familial Alzheimer’s disease mutations
(5XFAD) during the spontaneous alternation Y-maze
task. In addition, 7,8-DHF restores deficient TrkB signal-
ing in 5XFAD mice without affecting endogenous BDNF
levels. While 5XFAD mice exhibit elevations in the β-
secretase enzyme (BACE1) that initiates amyloid-β (Aβ)
generation, as observed in sporadic AD, 7,8-DHF blocks
BACE1 elevations and lowers the levels of the β-
secretase-cleaved C-terminal fragment of amyloid pre-
cursor protein (C99), Aβ40, and Aβ42 in the brains of
these mice. Most strikingly, they demonstrated that
BACE1 expression can be decreased by 7,8-DHF admin-
istration in wild-type mice, suggesting that BDNF-TrkB
signaling is also important for downregulating baseline
levels of BACE1. Hence, this study supports that TrkB ac-
tivation with systemic 7,8-DHF administration can ameli-
orate AD-associated memory deficits, attributable to
reductions in BACE1 expression and β-amyloidogenesis
[55]. Nevertheless, the authors employed a subchronic
paradigm (10 days intraperitonial injection) in aged 5X
FAD mice (12–15 months old mice). Since 5X FAD mice
develop amyloid plaques at 2 months old and exhibit cog-
nitive defects at 5 months of age, we employed a different
treatment strategy: feeding the mice at 2-months-old till
5-months-old and monitored the cognitive activity in
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Morris Water maze. In addition, we examined the amyloid
plaque deposit, synapse formation and long-term potenti-
ation (LTP) at the end of the treatment. Our data showed
that 7,8-DHF protects primary neurons from Aβ-induced
cell death and promotes dendrite branching and synapto-
genesis. Chronic oral administration of 7,8-DHF activates
TrkB signaling and prevents Aβ deposition in 5XFAD
mice [56]. In alignment with these findings, 7,8-DHF sig-
nificantly increases spine density and reduces synaptic and
neuronal loss in Cam/Tet-DTA, an inducible model of se-
vere neuronal loss in hippocampus and cortex, and dem-
onstrates substantial improvements in spatial memory in
the lesioned mice [58]. These results strongly suggest that
7,8-DHF represents a novel oral bioactive therapeutic
agent for treating AD.
7,8-DHF inhibits obesity through activating muscular TrkB
Obesity is a metabolic disorder with increasing preva-
lence worldwide. According to the World Health
Organization (WHO), more than 39 % (~1.9 billion) of
adults are overweight. Of these, over 600 million
(~13 %) are obese in 2014. These numbers have been
doubled since 1980. Therefore, developing effective
pharmacotherapy to control excess body weight gain is a
hot research direction nowadays.
In addition to the neurotrophic activities, BDNF/TrkB
signaling also plays a critical role in food intake and
body weight control. In rodents, pharmacological treat-
ments with BDNF induce a reduction of food intake,
whereas genetic models with reduced BDNF/TrkB sig-
naling display hyperphagia and obesity [67, 68]. Recent
evidence indicates that BDNF acts as an energy metabol-
ism regulator in both CNS and peripheral organs. It has
been reported that BDNF levels are low in obesity or pa-
tients with type 2 diabetes [68, 69]. BDNF is expressed
in non-neurogenic tissues, including skeletal muscle, and
exercise increases BDNF levels in brain, plasma and
skeletal muscle. Pederson et al. reported that BDNF in-
creased phosphorylation of AMP-activated protein kin-
ase (AMPK) and acetyl coenzyme A carboxylase (ACC)
and enhanced fatty oxidation both in vitro and ex vivo.
These data points to the fact that BDNF is a
contraction-inducible protein in skeletal muscle that is
capable of enhancing lipid oxidation via activation of
AMPK. Thus, BDNF appears to be an active player in
both neurobiology and peripheral metabolism [70].
Because BDNF has anti-obesity activity by suppressing
food intake, we thus initiated a test to see if 7,8-DHF
can be used to prevent the development of obesity. We
investigated the effect of 7,8-DHF (drinking the dis-
solved 7,8-DHF in water) on mouse body weight gain
under chow diet or high-fat diet (HFD) feeding for
6 months [49]. To our surprise, 7,8-DHF consumption
does not suppress food intake, which is in contrast to
BDNF administration. Nevertheless, we found that 7,8-
DHF significantly decreases the body weight gain in both
chow diet and HFD paradigms, with more striking effect
on HFD. The white adipocyte tissue (WAT) mass is sig-
nificantly decreased about 20–30 % in 7,8-DHF-treated
HFD group. Indirect calorimetry study showed that 7,8-
DHF treatment decreases RER (respiratory exchange ra-
tio), favoring the usage of lipid as the main fuel. Our
study also reveals the mechanism of the anti-obesity ac-
tions by 7,8-DHF. By performing experiments in animal
model and cell culture (C2C12) system, we identified
that 7,8-DHF mainly acts on the muscle TrkB receptors
to induce uncoupling protein 1 (UCP1) expression and
activates AMP-activated protein kinase (AMPK). As a
result, the energy expenditure and lipid oxidation in 7,8-
DHF activated muscle cells are increased, leading to the
lean phenotype observed. Unexpectedly, this anti-obesity
effect is predominantly associated with female mice but
not male mice, presumably due to estrogen content of
the animals. Mice with 7,8-DHF treatment also exhibit
improved blood insulin concentration, lower blood glu-
cose level and increased insulin sensitivity in tissues such
as liver, fat and muscles, suggesting 7,8-DHF is effective
in alleviating the obesity-induced diabetes as well. These
exciting findings identify a new function of BDNF/TrkB
signaling in the skeletal muscle that the cascade controls
cellular energy expenditure, which also provides the pre-
clinical evidence that 7,8-DHF administration is an
effective means to suppress body weight gain during en-
ergy surplus.
Perspectives and future directions
7,8-DHF is a broadly validated small molecule that imi-
tates the biological functions of BDNF via directly bind-
ing to the TrkB ECD to trigger TrkB receptor
dimerization and autophosphorylation [26]. It simulates
the physiological functions of BDNF like promoting
neuronal survival, elevating synaptogenesis and LTP on
aged hippocampal slides and enhancement of learning
and memory [26, 71, 72]. More important, 7,8-DHF dis-
plays a robust therapeutic efficacy in numerous neuro-
logical and metabolic diseases. However, it should be
noted that the dosage of 7,8-DHF in clinical application
has to be determined carefully as over-activation of the
TrkB signaling may result in devastating consequences.
In transgenic mice that overexpress BDNF in the fore-
brain, the animals exhibit spatial learning deficits at 2–3
months of age, followed by the emergence of spontan-
eous seizures at ~6 months, which is possibility a result
of neuronal hyperexciation [73–75]. Because BDNF acts
at central synapses in pain pathways both at spinal and
supraspinal levels, prolonged TrkB activation may also
interfere with the nociception pathway, leading to pain
hypersensitivity [76].
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Further investigations on the biochemical and mech-
anistic natures of 7,8-DHF are also necessary to boost its
applications. For instance, the precise molecular details
of how 7,8-DHF induces TrkB dimerization and activa-
tion are still unclear. For instance, how could 7,8-DHF
mimic so many aspects of the physiological activities of
the macromolecule BDNF, given that 7,8-DHF is only
254 dalton, which is 1 % of polypeptide hormone BDNF
in size? Further, the tyrosine phosphorylated residues on
TrkB intracellular domain and their relative abundance
are different after BDNF and 7,8-DHF stimulations [32].
What downstream effects may these molecular differ-
ences incur in view that although both PI3K/Akt and
MAPK downstream pathways are activated? Clearly, fur-
ther biochemical investigations into these aspects are
undoubtedly needed. Additional medicinal chemistry
work is also required for optimizing this promising lead
compound into a nanomolar binding affinity small mo-
lecular clinical candidate, which will not only provide an
innovative pharmacological intervention for treating
various human disorders but also present a useful tool
for dissecting the biological actions of BDNF/TrkB sig-
nalings. For example, the availability of a TrkB PET
tracer, which does not exist currently, would accelerate
TrkB therapeutic development and provide insight into
the role of TrkB and its expression levels in neuro-
psychiatric and neurodegenerative diseases, as well mon-
itoring the change of TrkB levels during antidepressant
or therapeutic neuro-regeneration treatments.
Conclusions
7,8-dihydroxyflavone is a promising small molecular
BDNF mimetic compound, which fully mimics the
physiological actions of BDNF from neuronal survival,
synpatogenesis, axonal regeneration etc. Notably, it is or-
ally bioactive and is safe for chronic treatment. It has
been extensively validated in various BDNFimplicated
disease models. Hence, it acts as a good lead compound
for further medicinal modification for optimizing its
therapeutic efficacy toward various BDNF-mediated hu-
man disorders.
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